AAPT Diagnostic Criteria for Chronic Abdominal, Pelvic, and Urogenital Pain: Irritable Bowel Syndrome

2018 ◽  
Vol 19 (3) ◽  
pp. 257-263 ◽  
Author(s):  
QiQi Zhou ◽  
Ursula Wesselmann ◽  
Lynn Walker ◽  
Linda Lee ◽  
Lonnie Zeltzer ◽  
...  
2019 ◽  
Vol 44 (12) ◽  
pp. 1329-1338
Author(s):  
Lauren A. Killian ◽  
Soo-Yeun Lee

Lower gastrointestinal (GI) symptoms are common among endurance athletes and can impair performance. Symptom characteristics are similar to irritable bowel syndrome (IBS). No previous research has examined IBS diagnosis (medically or by diagnostic criteria) within this population. The objectives of this study were to determine the prevalence of IBS among endurance athletes and examine their GI symptom management strategies. A previously validated, online questionnaire assessed IBS diagnosis, the meeting of IBS diagnostic criteria (Rome III or Manning), general GI symptoms, and symptom mitigation strategies of endurance athletes. The questionnaire was distributed to United States athletes completing a marathon, ultra-marathon, half-distance triathlon, or full-distance triathlon. Medically diagnosed IBS was reported by 2.8% of endurance athletes. The total prevalence of IBS (n = 430) was 9.8% (medical diagnosis and Rome III). Athletes with IBS experienced more frequent symptoms during exercise as well as at rest; however, only 47.6% had consulted a medical professional. Over 56% of athletes experienced at least 1 symptom sometimes, often, or always during training and competition and 18.6% had symptoms that sometimes or often interrupted/prevented training. Almost half (45.8%) of athletes and 80.0% of athletes with IBS reported trying nutritional modifications to help ease symptoms while 20.6% and 52.4% used over-the-counter medications, respectively. Novelty Most endurance athletes who suffer from IBS are undiagnosed, while even more experience GI symptoms but do not fit diagnostic criteria. Despite using various symptom management methods, endurance athletes are still experiencing symptoms and could potentially benefit from current IBS-mitigating strategies.


2019 ◽  
pp. 110-116
Author(s):  
D. I. Trukhan ◽  
V. V. Goloshubina ◽  
D. S. Ivanova

The problem of irritable bowel syndrome (IBS) remains relevant for practice internist and gastroenterologist, as evidenced by the large number of publications in recent years on this issue, affecting various aspects of the pathogenesis, clinical manifestations, diagnosis and treatment of IBS. The article describes the evolution of diagnostic criteria for IBS as part of an international consensus «Rome criteria». Lack of effect of the treatment of IBS ex juvantibus often not a consequence of an incorrect diagnosis, and due to the presence in the patient’s intestinal disorders microbiocenosis. In this situation, it is expedient to correct the microbial landscape of the intestine with the use of probiotic agents. Efficacy in reducing the symptoms of irritable bowel syndrome has reliably demonstrated specific strains of probiotics, such as Bifidobacterium infantis 35624.


2000 ◽  
Vol 118 (4) ◽  
pp. A396 ◽  
Author(s):  
Yuri A. Saito ◽  
G. Richard Locke ◽  
Charlene M. Prather ◽  
Alan R. Zinsmeister ◽  
Carol T. Van Dyke ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document